Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants.
暂无分享,去创建一个
G. Kang | S. Juvekar | A. Bavdekar | D. Nayak | P. Kulkarni | S. Babji | C. Kumar | M. Aslam | S. Lalwani | Subodh S. Gupta | N. Bedi | V. Kamath | S. Palkar | N. Ganguly | R. Kundu | A. Hegde | S. Desai | C. Maliye | N. Goyal | Varsha Parulekar | P. Niyogi | A. Raut | Muralidhar M. Kulkarni | A. Arya | J. Zade | Rakesh N. Patil | A. Kawade | N. Hanumante | Padmasani Venkatramanan | K. Uttam | A. Dharmadhikari | B. Garg | S. Jategaonkar | G. Dayma | D. Gaikwad | Rakesh Patil
[1] G. Kang,et al. A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants , 2018, Vaccine.
[2] N. Gogtay,et al. Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine☆ , 2018, Vaccine.
[3] M. Bhan,et al. A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India , 2018, Human vaccines & immunotherapeutics.
[4] P. Kulkarni,et al. Safety and tolerability of a liquid bovine rotavirus pentavalent vaccine (LBRV-PV) in adults. , 2018, Vaccine.
[5] G. Kang,et al. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants , 2017, Vaccine.
[6] E. Burnett,et al. Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006–2016 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] R. Montesano,et al. Impact of rotavirus vaccination on child mortality, morbidity, and rotavirus-related hospitalizations in Bolivia. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[8] J. Tate,et al. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh , 2017, Vaccine.
[9] S. Gairola,et al. Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®). , 2017, Vaccine.
[10] R. Grais,et al. Efficacy of a Low‐Cost, Heat‐Stable Oral Rotavirus Vaccine in Niger , 2017, The New England journal of medicine.
[11] B. M. Machado,et al. The impact of rotavirus vaccination on emergency department visits and hospital admissions for acute diarrhea in children under 5 years. , 2016, Revista da Associacao Medica Brasileira.
[12] L. Cuevas,et al. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis , 2016, Infectious Diseases of Poverty.
[13] J. Tate,et al. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] P. Kulkarni,et al. Bovine rotavirus pentavalent vaccine development in India. , 2014, Vaccine.
[15] G. Kang,et al. Human and bovine rotavirus strain antigens for evaluation of immunogenicity in a randomized, double-blind, placebo-controlled trial of a single dose live attenuated tetravalent, bovine-human-reassortant, oral rotavirus vaccine in Indian adults. , 2014, Vaccine.
[16] S. Bhave,et al. Immunogenicity and safety of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine (PRV) in Indian infants , 2013, Human vaccines & immunotherapeutics.
[17] T. Vesikari,et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. , 2011, Vaccine.
[18] G. Kang,et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants , 2009, Human vaccines.